Union européenne - grec - EMA (European Medicines Agency)

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Union européenne - grec - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Εμβόλια - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Η χρήση αυτού του εμβολίου θα πρέπει να γίνεται σύμφωνα με τις επίσημες συστάσεις.

Union européenne - grec - EMA (European Medicines Agency)

laboratorios hipra s.a - ζωντανός ge-tk- ιός βόειου έρπητα βοοειδούς τύπου 1, στέλεχος ceddel: 106.3-107.3 ccid50 - Ανοσολογικά - Βοοειδή - Για την ενεργητική ανοσοποίηση των βοοειδών από την ηλικία των τριών μηνών από τη ιός του έρπητα τύπου 1 (bohv-1), για να μειώσει τα κλινικά συμπτώματα λοιμώδους ρινοτραχειίτιδας των βοοειδών (ibr) και το πεδίο της απέκκρισης του ιού. Έναρξη ανοσίας: 21 ημέρες μετά την ολοκλήρωση του βασικού εμβολιασμού. Διάρκεια ανοσίας: 6 μήνες μετά την ολοκλήρωση του βασικού εμβολιασμού.

Grèce - grec - Εθνικός Οργανισμός Φαρμάκων

lavipharm ae - colistin mesilate sodium - ΕΝΕΣΙΜΟ ΞΗΡΟ - 500000ui/fl - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Grèce - grec - Εθνικός Οργανισμός Φαρμάκων

lavipharm ae - colistin mesilate sodium - ΕΝΕΣΙΜΟ ΞΗΡΟ - 1000000ui/fl - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Grèce - grec - Εθνικός Οργανισμός Φαρμάκων

andres pintaluba s.a., tarragona, spain (0000007211) pol.ind.agro-reus,,c/prudenci bertrana, no5,e - ΘΕΙΙΚΉ ΚΟΛΙΣΤΊΝΗ - ΔΙΑΛΥΜΑ ΓΙΑ ΧΟΡΗΓΗΣΗ ΜΕ ΠΟΣΙΜΟ ΝΕΡΟ/ΓΑΛΑ - 3.000.000 iu/ml - colistin sulfate 3000000,00 sol.wa.mil 3.000.000 iu/ml - colistin - Βοοειδή; Πρόβατα; Χοίροι; Ορνίθια; Ινδόρνιθες - Χρόνοι αναμονής: Βοοειδή 1 Ημέρες Κρέας και εδώδιμοι ιστοί; Πρόβατα 1 Ημέρες Κρέας και εδώδιμοι ιστοί; Χοίροι 1 Ημέρες Κρέας και εδώδιμοι ιστοί; Ινδόρνιθες 1 Ημέρες Κρέας και εδώδιμοι ιστοί; Ορνίθια 1 Ημέρες Κρέας και εδώδιμοι ιστοί; Ορνίθια 0 Ημέρες Αυγά; Ινδόρνιθες 0 Ημέρες Αυγά

Grèce - grec - Εθνικός Οργανισμός Φαρμάκων

ΑΡΗΤΗ a.e. Τατοϊου 52,, 136 77 136 77, Αχαρνές, 210.8002650 - colistin mesilate sodium - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 1000000 iu/vial - colistin mesilate sodium 1.000.000iu - colistin

Grèce - grec - Εθνικός Οργανισμός Φαρμάκων

ΑΡΗΤΗ a.e. Τατοϊου 52,, 136 77 136 77, Αχαρνές, 210.8002650 - colistin mesilate sodium - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 2000000 iu/vial - colistin mesilate sodium 2.000.000iu - colistin

Union européenne - grec - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - Εμβόλια - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Union européenne - grec - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Αντινεοπλασματικοί παράγοντες - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.